Debt AdvisoryHealthcareSIGNED
Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics
Value
$58M
Target
Rouge Therapeutics
Angelini Ventures and the European Investment Bank (EIB) have co-led a $58 million Series A financing round for Rouge Therapeutics. This funding will advance the development of a first-in-class treatment for Hereditary Hemorrhagic Telangiectasia.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.